The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence
The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/5/1072 |
| _version_ | 1797598085026676736 |
|---|---|
| author | Mykhailo Buchynskyi Iryna Kamyshna Valentyn Oksenych Nataliia Zavidniuk Aleksandr Kamyshnyi |
| author_facet | Mykhailo Buchynskyi Iryna Kamyshna Valentyn Oksenych Nataliia Zavidniuk Aleksandr Kamyshnyi |
| author_sort | Mykhailo Buchynskyi |
| collection | DOAJ |
| description | The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a pervasive public health concern intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and MAFLD is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among MAFLD patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of MAFLD on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations. |
| first_indexed | 2024-03-11T03:14:24Z |
| format | Article |
| id | doaj.art-6fbc4d6afb1b470fa877accca5b52fa7 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T03:14:24Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-6fbc4d6afb1b470fa877accca5b52fa72023-11-18T03:38:33ZengMDPI AGViruses1999-49152023-04-01155107210.3390/v15051072The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current EvidenceMykhailo Buchynskyi0Iryna Kamyshna1Valentyn Oksenych2Nataliia Zavidniuk3Aleksandr Kamyshnyi4Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, UkraineDepartment of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, UkraineDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, NorwayDepartment of Infectious Diseases with Epidemiology, Dermatology and Venerology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, UkraineDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, UkraineThe global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a pervasive public health concern intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and MAFLD is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among MAFLD patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of MAFLD on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.https://www.mdpi.com/1999-4915/15/5/1072fatty liver diseaseMAFLDcoronavirus disease 2019SARS-CoV-2 |
| spellingShingle | Mykhailo Buchynskyi Iryna Kamyshna Valentyn Oksenych Nataliia Zavidniuk Aleksandr Kamyshnyi The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence Viruses fatty liver disease MAFLD coronavirus disease 2019 SARS-CoV-2 |
| title | The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence |
| title_full | The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence |
| title_fullStr | The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence |
| title_full_unstemmed | The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence |
| title_short | The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence |
| title_sort | intersection of covid 19 and metabolic associated fatty liver disease an overview of the current evidence |
| topic | fatty liver disease MAFLD coronavirus disease 2019 SARS-CoV-2 |
| url | https://www.mdpi.com/1999-4915/15/5/1072 |
| work_keys_str_mv | AT mykhailobuchynskyi theintersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT irynakamyshna theintersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT valentynoksenych theintersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT nataliiazavidniuk theintersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT aleksandrkamyshnyi theintersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT mykhailobuchynskyi intersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT irynakamyshna intersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT valentynoksenych intersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT nataliiazavidniuk intersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence AT aleksandrkamyshnyi intersectionofcovid19andmetabolicassociatedfattyliverdiseaseanoverviewofthecurrentevidence |